Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ambroxol salbutamol enteric particles

An ambroxoxalbutamol and enteric-coated technology, which is applied to the medical preparations of non-active ingredients, respiratory diseases, organic active ingredients, etc., can solve the problem of unsatisfactory product stability, no reports of enteric-coated particles, and easy side effects. Products and other problems, to achieve the effect of increasing the content of active ingredients, treating respiratory diseases, and improving stability

Inactive Publication Date: 2016-03-02
CP PHARMA QINGDAO CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In the prior art, dosage forms such as solutions and granules containing ambroxol hydrochloride and salbutamol sulfate have existed, but there are no reports of enteric-coated granules
[0007] In addition, albuterol sulfate and ambroxol hydrochloride are the active ingredients in the same minimum preparation unit. During long-term storage, due to possible chemical compatibility changes between the ingredients, by-products are likely to be produced, which will reduce the effect or increase side effects. Product stability not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ambroxol salbutamol enteric particles
  • Ambroxol salbutamol enteric particles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] prescription:

[0050] The core is made of the following components by weight:

[0051] Salbutamol sulfate: 12g;

[0052] Ambroxol hydrochloride: 15g;

[0053] Poloxamer 188: 8g;

[0054] Meglumine: 12g;

[0055] Mannitol: 18g;

[0056] Lactose: 60g;

[0057] Sodium carboxymethyl starch: 5g;

[0058] Povidone: Appropriate amount.

[0059] The enteric coating layer is made of the following components by weight: 15 g of cellulose acetate phthalate.

[0060] Preparation:

[0061] 1) Weigh the raw and auxiliary materials of the prescription amount, pass through a 100-mesh sieve for subsequent use;

[0062] 2) Add distilled water to the sieved povidone and cellulose acetate phthalate respectively to make a binder solution and a coating solution;

[0063] 3) Mix the sieved salbutamol sulfate, ambroxol hydrochloride, poloxamer 188, meglumine, mannitol, lactose and carboxymethyl starch sodium in equal increments, and add the above adhesive solution to prepare into soft...

Embodiment 2

[0067] prescription:

[0068] Core:

[0069] Salbutamol sulfate: 10g;

[0070] Ambroxol hydrochloride: 15g;

[0071] Poloxamer 188: 5g;

[0072] Meglumine: 15g;

[0073] Mannitol: 15g;

[0074] Dextrin: 80g;

[0075] Microcrystalline cellulose: 2g;

[0076] Hypromellose: Appropriate amount.

[0077] Coating layer: 10 g of cellulose acetate trimellitate.

[0078] Preparation:

[0079] 1) Weigh the raw and auxiliary materials of the prescription amount, pass through a 100-mesh sieve for subsequent use;

[0080] 2) Take the sieved hypromellose and cellulose acetate trimellitate and add distilled water respectively to make a binder solution and a coating solution;

[0081] 3) Mix the sieved salbutamol sulfate, ambroxol hydrochloride, poloxamer 188, meglumine, mannitol, dextrin and microcrystalline cellulose in equal increments, and add the above adhesive solution to prepare into soft material;

[0082] 4) After granulating with a 40-mesh sieve, dry at 60°C for 30 minut...

Embodiment 3

[0085] prescription:

[0086] Core:

[0087] Salbutamol sulfate: 15g;

[0088] Ambroxol hydrochloride: 20g;

[0089] Poloxamer 188: 10g;

[0090] Meglumine: 12g;

[0091] Mannitol: 20g;

[0092] Starch: 60g;

[0093] Microcrystalline cellulose: 4g;

[0094] Povidone: Appropriate amount.

[0095] Coating layer: 20 g of hydroxypropyl cellulose phthalate.

[0096] Preparation:

[0097] 1) Weigh the raw and auxiliary materials of the prescription amount, pass through a 100-mesh sieve for subsequent use;

[0098] 2) Take povidone and hydroxypropyl cellulose phthalate after sieving and add distilled water respectively to make binder solution and coating solution;

[0099] 3) Mix the sieved albuterol sulfate, ambroxol hydrochloride, poloxamer 188, meglumine, mannitol, starch and microcrystalline cellulose in equal increments, and add the above binder solution to prepare soft material;

[0100] 4) After granulating with a 40-mesh sieve, dry at 60°C for 60 minutes, pass thr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to ambroxol salbutamol enteric particles, and belongs to the field of pharmaceutic preparations. A proper amount of poloxamer 188, meglumine and mannitol are added in the enteric particles, stability and bioavailability of ambroxol hydrochloride and salbutamol sulfate in preparations can be improved remarkably, the quality is stable, the effect is remarkable, and respiratory system diseases such as acute and chronic bronchitis and asthma can be treated effectively.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an ambroxoxalbutamol enteric-coated granule and a preparation method thereof. Background technique [0002] Respiratory system disease is a common and frequently-occurring disease. The main lesions are in the trachea, bronchi, lungs, and chest cavity. Mild cases often cause coughing, chest pain, and respiratory problems. Severe cases have dyspnea, hypoxia, and even death due to respiratory failure. The death rate in the city is the third, while in the countryside it is the first. What should be paid more attention to is that due to air pollution, smoking, population aging and other factors, chronic obstructive pulmonary disease (referred to as COPD, including chronic bronchitis, emphysema, pulmonary heart disease), bronchial asthma, lung cancer, etc. , Pulmonary diffuse interstitial fibrosis, and the morbidity and mortality of diseases such as pulmonary infection are i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/16A61K31/137A61K47/10A61K47/26A61P11/00A61P11/06
CPCA61K9/1623A61K9/1641A61K31/137A61K47/38A61K2300/00
Inventor 王明刚陈阳生任莉
Owner CP PHARMA QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com